Jason Goodson, Chief Business Officer at PleoPharma, will take the stage at the San Diego Convention Center on June 23 at 12:15 PM in Theater 4. His presentation serves as a platform to share clinical data regarding cannabis withdrawal and provide a status report on the firm’s lead investigational asset, PP-01. This once-daily oral treatment is currently moving through Phase 3 clinical trials, with the initial patient recently receiving a dose.
PleoPharma Heads to BIO 2026 to Showcase Cannabis Addiction Treatment
With over 20 million Americans struggling with cannabis use disorder, the pressure to develop effective medical interventions is rising. PleoPharma, Inc. is set to address this clinical gap at the BIO International Convention in San Diego, where the company will detail its progress on a new medication-assisted therapy.
PP-01 represents a potential first-in-class solution for patients attempting to navigate the severe withdrawal symptoms—such as irritability, anxiety, and sleep disruption—that frequently trigger relapse. By targeting suppressed CB1 receptors and neurotransmitter dysregulation in the mesolimbic reward pathway, the drug aims to offer a stable, tolerable option for those suffering from addiction. Given that 1.4 million people sought treatment for the condition in 2024 despite a lack of approved medication-assisted therapies, the clinical need for such an intervention remains high.
Comments (0)
No comments yet. Be the first!